^
    1year
    Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model (AACR 2023)
    RNA sequencing analysis of mouse tumors revealed that the combination of T1-44 and vactosertib significantly altered the expression of genes involved in cancer progression, such as cell migration, extracellular matrix, and apoptotic processes. These data demonstrate that the combination therapy of T1-44 with vactosertib is synergistic for pancreatic cancer, suggesting that this novel combination therapy has value in the treatment strategy of patients with pancreatic cancer.
    Preclinical
    |
    PRMT5 (Protein Arginine Methyltransferase 5) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    vactosertib (TEW-7197) • T1-44